Organization and Basis of Presentation - Schedule of Error Corrections (Details) - USD ($)	3 Months Ended		6 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Consolidated Balance Sheets
Total assets	$ 101,838,000	$ 92,229,000	$ 101,838,000	$ 257,448,000	$ 19,762,000
Contract liabilities	1,669,000	2,514,000	1,669,000	513,000	0
Accrued expenses and other current liabilities	2,392,000	806,000	2,392,000	6,974,000	525,000
Total current liabilities	5,920,000	3,903,000	5,920,000	17,312,000	1,156,000
Accumulated deficit	(89,561,000)	(33,228,000)	(89,561,000)	(171,363,000)	(29,172,000)
Total shareholders’ deficit	(87,440,000)	(31,475,000)	(87,440,000)	209,275,000	(27,862,000)	$ (20,735,000)
Total liabilities, convertible preferred stock, and shareholders’ deficit	101,838,000	92,229,000	101,838,000	257,448,000	19,762,000
Consolidated Statements of Operations and Comprehensive Loss
Revenue	845,000	516,000	1,361,000	8,804,000	200,000
Cost of revenue	845,000	516,000	1,361,000	13,688,000	417,000
Gross loss	0	0	0	(4,884,000)	(217,000)
Selling, general, and administrative	4,260,000	2,152,000	6,412,000	30,386,000	3,713,000
Research and development	2,665,000	1,608,000	4,273,000	13,478,000	3,583,000
Total operating expenses	6,925,000	3,760,000	10,685,000	43,864,000	7,296,000
Operating loss	(6,925,000)	(3,760,000)	(10,685,000)	(48,748,000)	(7,513,000)
Net loss	(56,333,000)	(4,056,000)	(60,389,000)	(142,191,000)	(7,437,000)
Total comprehensive loss	$ (56,335,000)	$ (4,068,000)	$ (60,403,000)	$ (142,195,000)	$ (7,437,000)
Loss per share – Basic (in dollars per share)	$ (10.68)	$ (0.84)	$ (11.92)	$ (11.88)	$ (0.93)
Loss per share – Diluted (in dollars per share)	$ (10.68)	$ (0.84)	$ (11.92)	$ (11.88)	$ (0.93)
Decrease to accumulated deficit	$ 200,000	$ 100,000
Consolidated Statements of Cash Flows
Net loss	(56,333,000)	(4,056,000)	$ (60,389,000)	$ (142,191,000)	$ (7,437,000)
Changes in assets and liabilities:
Accrued expenses and other current liabilities		227,000	1,113,000	4,245,000	212,000
Contract liabilities		2,514,000	1,669,000	123,000	0
Net cash used in operating activities		(625,000)	(8,502,000)	$ (31,055,000)	$ (7,002,000)
Initially reported
Consolidated Balance Sheets
Total assets	101,838,000	92,229,000	101,838,000
Contract liabilities	1,944,000	2,439,000	1,944,000
Accrued expenses and other current liabilities	2,663,000	997,000	2,663,000
Total current liabilities	6,466,000	4,019,000	6,466,000
Accumulated deficit	(90,107,000)	(33,344,000)	(90,107,000)
Total shareholders’ deficit	(87,986,000)	(31,591,000)	(87,986,000)			$ (20,735,000)
Total liabilities, convertible preferred stock, and shareholders’ deficit	101,838,000	92,229,000	101,838,000
Consolidated Statements of Operations and Comprehensive Loss
Revenue	687,000	591,000	1,086,000
Cost of revenue	687,000	591,000	1,086,000
Gross loss	0	0	0
Selling, general, and administrative	4,340,000	2,343,000	6,683,000
Research and development	2,823,000	1,533,000	4,548,000
Total operating expenses	7,163,000	3,876,000	11,231,000
Operating loss	(7,163,000)	(3,876,000)	(11,231,000)
Net loss	(56,571,000)	(4,172,000)	(60,935,000)
Total comprehensive loss	$ (56,573,000)	$ (4,184,000)	$ (60,949,000)
Loss per share – Basic (in dollars per share)	$ (10.72)	$ (0.86)	$ (12.03)
Loss per share – Diluted (in dollars per share)	$ (10.72)	$ (0.86)	$ (12.03)
Consolidated Statements of Cash Flows
Net loss	$ (56,571,000)	$ (4,172,000)	$ (60,935,000)
Changes in assets and liabilities:
Accrued expenses and other current liabilities		418,000	1,384,000
Contract liabilities		2,439,000	1,944,000
Net cash used in operating activities		(625,000)	(8,502,000)
Adjustments
Consolidated Balance Sheets
Total assets	0	0	0
Contract liabilities	(275,000)	75,000	(275,000)
Accrued expenses and other current liabilities	(271,000)	(191,000)	(271,000)
Total current liabilities	(546,000)	(116,000)	(546,000)
Accumulated deficit	546,000	116,000	546,000
Total shareholders’ deficit	546,000	116,000	546,000
Total liabilities, convertible preferred stock, and shareholders’ deficit	0	0	0
Consolidated Statements of Operations and Comprehensive Loss
Revenue	158,000	(75,000)	275,000
Cost of revenue	158,000	(75,000)	275,000
Gross loss	0	0	0
Selling, general, and administrative	(80,000)	(191,000)	(271,000)
Research and development	(158,000)	75,000	(275,000)
Total operating expenses	(238,000)	(116,000)	(546,000)
Operating loss	238,000	116,000	546,000
Net loss	238,000	116,000	546,000
Total comprehensive loss	$ 238,000	$ 116,000	$ 546,000
Loss per share – Basic (in dollars per share)	$ 0.04	$ 0.02	$ 0.11
Loss per share – Diluted (in dollars per share)	$ 0.04	$ 0.02	$ 0.11
Consolidated Statements of Cash Flows
Net loss	$ 238,000	$ 116,000	$ 546,000
Changes in assets and liabilities:
Accrued expenses and other current liabilities		(191,000)	(271,000)
Contract liabilities		75,000	(275,000)
Net cash used in operating activities		$ 0	$ 0